Marksans Pharma is engaged in the Business of Formulation of pharmaceutical products. Financial Results: Marksans Pharma Ltd reported Revenues for Q4FY24 of
Marksans Pharma Limited
-(MARKSANS)
XNSE:MAPMYINDIA, XBOM:MAPMYINDIA
Marksans Pharma Ltd Q3FY24; 34% rise in Profits
Marksans Pharma is engaged in the Business of Formulation of pharmaceutical products. Financial Results: Marksans Pharma Ltd reported Revenues for Q3FY24 of
Marksans Pharma Limited Q2 FY24 Earnings Conference Call Insights
Key highlights from Marksans Pharma Limited (MARKSANS) Q2 FY24 Earnings Concall Financial Performance Revenues grew 17% year-on-year to INR531 crores in Q2
Marksans Pharma Ltd Q1FY24; 17% rise in Profits
Marksans Pharma is engaged in the Business of Formulation of pharmaceutical products. Financial Results: Marksans Pharma Ltd reported Revenues for Q1FY24 of
Marksans Pharma Limited Q3 FY23 Earnings Conference Call Insights
Key highlights from Marksans Pharma Limited (MARKSANS) Q3 FY23 Earnings Concall Q&A Highlights: [00:08:54] Riddhesh Gandhi from Discovery Capital asked why there
Marksans Pharma Limited (MARKSANS) Q3 FY23 Earnings Concall Transcript
Marksans Pharma Limited (NSE:MARKSANS) Q3 FY23 Earnings Concall dated Feb. 14, 2023. Corporate Participants: Mark Saldanha -- Managing Director and Chief Executive Officer Jitendra
Marksans Pharma(NSE:MARKSANS): Everything You Need to Know | Stock up 30% in 3 Months
Marksans Pharma (NSE:MARKSANS) is a mid-sized pharmaceutical company with a large presence in the US, UK, Australia, and New Zealand markets. forward-integrated
Marksans Pharma Limited Q2 FY23 Earnings Conference Call Insights
Key highlights from Marksans Pharma Limited (MARKSANS) Q2 FY23 Earnings Concall Q&A Highlights: [00:12:45] Madhav Shastri asked about the new acquisition made
Marksans Pharma Limited Q1 FY23 Earnings Conference Call Insights
https://youtu.be/9PAJ7vTTG5E Key highlights from Marksans Pharma Limited (MARKSANS) Q1 FY23 Earnings Concall Management Update: MARKSANS said it aims to increase its R&D
Marksans Pharma Limited Q4 FY22 Earnings Conference Call Insights
Key highlights from Marksans Pharma Limited (MARKSANS) Q4 FY22 Earnings Concall Q&A Highlights: Vijay Nahar - Individual Investor - Analyst Challenges